Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Ticagrelor is a direct acting on the P2Y12 receptor blocker, which provides faster and greater platelet inhibition than clopidogrel. However, several studies suggested that in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention (PCI), ticagrelor exhibits...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Liu, Hui-Liang, Wei, Yu-Jie, Jin, Zhi-Geng, Zhang, Jiao, Ding, Peng, Yang, Sheng-Li, Luo, Jian-Ping, Ma, Dong-Xing, Liu, Ying, Han, Wei
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2016
Assuntos:
3400
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4900712/
https://ncbi.nlm.nih.gov/pubmed/27258504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003756
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados